verapamil has been researched along with 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2h-tetrazolium hydroxide in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Canevari, S; D'Ascenzo, S; Dolo, V; Millimaggi, D; Miotti, S; Pavan, A; Violini, S | 1 |
1 other study(ies) available for verapamil and 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-((phenylamino)carbonyl)-2h-tetrazolium hydroxide
| Article | Year |
|---|---|
Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flow Cytometry; Fluorouracil; Humans; Inhibitory Concentration 50; Methotrexate; Mitochondrial Proteins; Multidrug Resistance-Associated Proteins; Ovarian Neoplasms; Paclitaxel; Phenotype; Ribosomal Proteins; Saccharomyces cerevisiae Proteins; Tetrazolium Salts; Time Factors; Tubulin; Verapamil; Vinblastine | 2004 |